Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Management of Major Depressive Disorder 

A joint clinical practice guideline (CPG) from the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) provides key recommendations for the management of major depressive disorder (MDD). Important new evidence informed “changes to prior recommendations on pharmacologic management, pharmacogenomics, psychotherapy, complementary and alternative therapies, and the use of telemedicine,” the authors write.

“We hope the updated CPG will improve treatment decision making and inform future research directions,” they conclude. “The guideline work group found a broad and expanding range of treatment options for major depression. The expansion of psychotherapy options, the inclusion of ketamine and esketamine as interventions for patients who have not responded to pharmacologic options, and the expansion of the recommendation for bright light therapy increase choices for patients and providers. In addition, considerations regarding psychedelic medications, pharmacogenomics, treatment modalities, and the lack of sufficient information to address specific patient populations highlight areas requiring additional research.”

Source: Annals of Internal Medicine